Trial Profile
A randomized, evaluator-blinded, comparative study to evaluate the efficacy and safety of different injection volumes of botulinum toxin type A, Azzalure, in the glabellar lines
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; Therapeutic Use
- Sponsors Galderma Research & Development; Q-Med
- 12 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 04 Jun 2014 According to the ClinicalTrials.gov record, planned end date changed from 17 Jan 2015 to 1 Nov 2014.
- 04 Jun 2014 New source identified and integrated (ClinicalTrials.gov record: NCT02108158)